These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 26312160)

  • 1. Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma.
    Derenzini E; Iacobucci I; Agostinelli C; Imbrogno E; Storlazzi CT; L Abbate A; Casadei B; Ferrari A; Di Rora AG; Martinelli G; Pileri S; Zinzani PL
    Exp Hematol Oncol; 2015; 4():24. PubMed ID: 26312160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma.
    Derenzini E; Agostinelli C; Imbrogno E; Iacobucci I; Casadei B; Brighenti E; Righi S; Fuligni F; Ghelli Luserna Di Rorà A; Ferrari A; Martinelli G; Pileri S; Zinzani PL
    Oncotarget; 2015 Mar; 6(9):6553-69. PubMed ID: 25544753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma.
    Hüllein J; Słabicki M; Rosolowski M; Jethwa A; Habringer S; Tomska K; Kurilov R; Lu J; Scheinost S; Wagener R; Huang Z; Lukas M; Yavorska O; Helfrich H; Scholtysik R; Bonneau K; Tedesco D; Küppers R; Klapper W; Pott C; Stilgenbauer S; Burkhardt B; Löffler M; Trümper LH; Hummel M; Brors B; Zapatka M; Siebert R; Kreuz M; Keller U; Huber W; Zenz T
    Cancer Res; 2019 Jun; 79(12):3125-3138. PubMed ID: 31000522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Interactions of DNA Repair, Telomere Homeostasis, and p53 Mutational Status in Solid Cancers: Risk, Prognosis, and Prediction.
    Vodicka P; Andera L; Opattova A; Vodickova L
    Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33513745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy.
    Ronchetti L; Melucci E; De Nicola F; Goeman F; Casini B; Sperati F; Pallocca M; Terrenato I; Pizzuti L; Vici P; Sergi D; Di Lauro L; Amoreo CA; Gallo E; Diodoro MG; Pescarmona E; Vitale I; Barba M; Buglioni S; Mottolese M; Fanciulli M; De Maria R; Maugeri-Saccà M
    Int J Cancer; 2017 Jun; 140(11):2587-2595. PubMed ID: 28233295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
    Mota A; Triviño JC; Rojo-Sebastian A; Martínez-Ramírez Á; Chiva L; González-Martín A; Garcia JF; Garcia-Sanz P; Moreno-Bueno G
    BMC Cancer; 2015 Nov; 15():940. PubMed ID: 26620706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 in breast cancer subtypes and new insights into response to chemotherapy.
    Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
    Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tp53 deletion in B lineage cells predisposes mice to lymphomas with oncogenic translocations.
    Rowh MA; DeMicco A; Horowitz JE; Yin B; Yang-Iott KS; Fusello AM; Hobeika E; Reth M; Bassing CH
    Oncogene; 2011 Nov; 30(47):4757-64. PubMed ID: 21625223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of TP53 mutations on the prognosis of patients with early stage non-small cell lung cancer may depend on the intratumor heterogeneity of the mutations.
    Lee SY; Jeon HS; Hwangbo Y; Jeong JY; Park JY; Lee EJ; Jin G; Shin KM; Yoo SS; Lee J; Lee EB; Cha SI; Kim CH; Park JY
    Mol Carcinog; 2015 Feb; 54(2):93-101. PubMed ID: 24038464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer.
    Zhang LL; Kan M; Zhang MM; Yu SS; Xie HJ; Gu ZH; Wang HN; Zhao SX; Zhou GB; Song HD; Zheng CX
    Int J Cancer; 2017 Jan; 140(1):103-108. PubMed ID: 27646734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations.
    Gebauer N; Bernard V; Gebauer W; Thorns C; Feller AC; Merz H
    Leuk Lymphoma; 2015 Jan; 56(1):179-85. PubMed ID: 24679006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
    Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
    Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells.
    Ferrao PT; Bukczynska EP; Johnstone RW; McArthur GA
    Oncogene; 2012 Mar; 31(13):1661-72. PubMed ID: 21841818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-cancer inference of intra-tumor heterogeneity reveals associations with different forms of genomic instability.
    Raynaud F; Mina M; Tavernari D; Ciriello G
    PLoS Genet; 2018 Sep; 14(9):e1007669. PubMed ID: 30212491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A role for c-myc in DNA damage-induced apoptosis in a human TP53-mutant small-cell lung cancer cell line.
    Supino R; Perego P; Gatti L; Caserini C; Leonetti C; Colantuono M; Zuco V; Carenini N; Zupi G; Zunino F
    Eur J Cancer; 2001 Nov; 37(17):2247-56. PubMed ID: 11677115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The intratumor heterogeneity of TP53 gene mutations in canine histiocytic sarcoma.
    Asada H; Ichii O; Tomiyasu H; Uchida K; Chambers JK; Goto-Koshino Y; Ohno K; Kon Y; Tsujimoto H
    J Vet Med Sci; 2019 Mar; 81(3):353-356. PubMed ID: 30662044
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Na K; Sung JY; Kim HS
    Anticancer Res; 2017 Dec; 37(12):6697-6703. PubMed ID: 29187446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New clues to the molecular pathogenesis of Burkitt lymphoma revealed through next-generation sequencing.
    Greenough A; Dave SS
    Curr Opin Hematol; 2014 Jul; 21(4):326-32. PubMed ID: 24867287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the DNA Damage Response in OSCC with TP53 Mutations.
    Lindemann A; Takahashi H; Patel AA; Osman AA; Myers JN
    J Dent Res; 2018 Jun; 97(6):635-644. PubMed ID: 29489434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.